ICC 2019

Vladimir Torchilin

Vladimir Torchilin, Speaker at Cancer Conferences
Northeastern University, United States
Title : Next generation of combination nanopreparations for multidrug resistant cancer


Pharmaceutical nanocarriers, including liposomes and polymeric micelles, are frequently used for the delivery of a broad variety of both soluble and poorly soluble anticancer drugs to enhance their in vivo efficiency. The next generation of drug delivery systems for cancer, especially, for multidrug resistant (MDR) tumors, includes multifunctional stimuli-responsive nanocarriers, i.e. nanocarriers that can circulate long; target the site of the disease; respond local stimuli characteristic of the pathological site by, for example, releasing an entrapped drug or deleting a protective coating to facilitate the contact between drug-loaded nanocarriers and target cells; and even provide an enhanced intracellular delivery of the drug with its subsequent delivery to specific intracellular organelles. Among new developments to be considered in the area of multifunctional pharmaceutical nanocarriers for MDR tumors are: drug- or/and siRNA-loaded delivery systems additionally decorated with cell-penetrating peptides for the enhanced intracellular delivery; “smart” multifunctional drug delivery systems, which can reveal/expose temporarily hidden functions under the action of certain local stimuli characteristic for the tumor microenvironment (such as lowered pH, redox-conditions, hypoxia, or locally increased expression of certain enzymes); new means for controlled delivery and release of siRNA; and approaches for intracellular drug delivery and organelle targeting. The application of nanocarriers co-loaded with siRNA and drugs to treat specifically MDR tumors will be specifically addressed.


Vladimir Torchilin got his M.S, Ph.D., and D.Sc. from the Moscow State University and serves currently as a University Distinguished Professor and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. He has published more than 400 papers, more than 150 reviews and book chapters, wrote and edited 13 books, and holds more than 40 patents. Google Scholar shows more than 60,000 citations of his papers with H-index of 111. He is Editor-in-Chief of Current Drug Discovery Technologies and Drug Delivery, Co-Editor of Current Pharmaceutical Biotechnology and on the Editorial Boards of many journals. He received more than $30 M from the government and industry in research funding. He has multiple honors and awards and in 2011, Times Higher Education ranked him number 2 among top world scientists in pharmacology for the period of 2000-2010.